Patents by Inventor Rifaat Safadi

Rifaat Safadi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of neuroligin 4-neurexin 1-beta protein-protein interaction for treatment of liver disorders
    Patent number: 11718666
    Abstract: Method for treating, attenuating and/or preventing progression of a liver disorder in a subject, the method including administering a therapeutically effective amount of an agent capable of interfering with, inhibiting and/or preventing neuroligin 4 (NLGn4)-Neurexin 1-beta (Nrx1b) protein-protein interaction; and compositions including the agent.
    Type: Grant
    Filed: July 29, 2021
    Date of Patent: August 8, 2023
    Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventor: Rifaat Safadi
  • INHIBITORS OF NEUROLIGIN 4-NEUREXIN 1-BETA PROTEIN-PROTEIN INTERACTION FOR TREATMENT OF LIVER DISORDERS
    Publication number: 20220010009
    Abstract: Method for treating, attenuating and/or preventing progression of a liver disorder in a subject, the method including administering a therapeutically effective amount of an agent capable of interfering with, inhibiting and/or preventing neuroligin 4 (NLGn4)-Neurexin 1-beta (Nrx1b) protein-protein interaction; and compositions including the agent.
    Type: Application
    Filed: July 29, 2021
    Publication date: January 13, 2022
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventor: Rifaat SAFADI
  • Inhibitors of neuroligin 4-neurexin 1-beta protein-protein interaction for treatment of liver disorders
    Patent number: 11098116
    Abstract: Method for treating, attenuating and/or preventing progression of a liver disorder in a subject, the method including administering a therapeutically effective amount of an agent capable of interfering with, inhibiting and/or preventing neuroligin 4 (NLGn4)-Neurexin 1-beta (Nrx1b) protein-protein interaction; and compositions including the agent.
    Type: Grant
    Filed: May 9, 2019
    Date of Patent: August 24, 2021
    Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventor: Rifaat Safadi
  • INHIBITORS OF NEUROLIGIN 4-NEUREXIN 1-BETA PROTEIN-PROTEIN INTERACTION FOR TREATMENT OF LIVER DISORDERS
    Publication number: 20190389948
    Abstract: Method for treating, attenuating and/or preventing progression of a liver disorder in a subject, the method including administering a therapeutically effective amount of an agent capable of interfering with, inhibiting and/or preventing neuroligin 4 (NLGn4)-Neurexin 1-beta (Nrx1b) protein-protein interaction; and compositions including the agent.
    Type: Application
    Filed: May 9, 2019
    Publication date: December 26, 2019
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventor: Rifaat SAFADI
  • Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD)
    Patent number: 10266897
    Abstract: A kit having a means for isolating an immune cell population from a biological sample of a patient; and at least one agent capable of detecting NLGn4 gene product expression level.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: April 23, 2019
    Assignee: Hadasit Medical Research and Development Ltd.
    Inventor: Rifaat Safadi
  • MODULATION OF NLGn4 EXPRESSION, NK CELL ACTIVITY IN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
    Publication number: 20180202001
    Abstract: A kit having a means for isolating an immune cell population from a biological sample of a patient; and at least one agent capable of detecting NLGn4 gene product expression level.
    Type: Application
    Filed: March 7, 2018
    Publication date: July 19, 2018
    Inventor: Rifaat SAFADI
  • INHIBITORS OF NEUROLIGIN 4 - NEUREXIN 1-BETA PROTEIN-PROTEIN INTERACTION FOR TREATMENT OF LIVER DISORDERS
    Publication number: 20180111989
    Abstract: Provided is a method for treating, attenuating and/or preventing progression of a liver disorder in a subject, the method including administering a therapeutically effective amount of an agent capable of interfering with, inhibiting and/or preventing neuroligin 4 (NLGn4)-Neurexin 1-beta (Nrx1b) protein-protein interaction. Also provided are compositions including the agent.
    Type: Application
    Filed: March 31, 2016
    Publication date: April 26, 2018
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventor: Rifaat SAFADI
  • Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD)
    Patent number: 9944988
    Abstract: The present invention provides a method of diagnosing and/or monitoring a liver disorder in a subject. The method calls for isolating an immune cell population from a biological sample of the subject; and detecting expression level of an NLGn4 gene product in the immune cell population using NLGn4 specific primers or NLGn4 specific probes.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: April 17, 2018
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventor: Rifaat Safadi
  • MODULATION OF NLGn4 EXPRESSION, NK CELL ACTIVITY IN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
    Publication number: 20160369347
    Abstract: The present invention provides a method of diagnosing and/or monitoring a liver disorder in a subject. The method calls for isolating an immune cell population from a biological sample of the subject; and detecting expression level of an NLGn4 gene product in the immune cell population using NLGn4 specific primers or NLGn4 specific probes.
    Type: Application
    Filed: September 6, 2016
    Publication date: December 22, 2016
    Inventor: Rifaat SAFADI
  • Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD)
    Patent number: 9469855
    Abstract: The present invention provides a method of treating, attenuating or preventing a liver disorder by inhibiting NGn4 expression and thereby modulating the activity of NK cells. The present invention further relates to diagnosing a liver disorder by evaluating NLGn4 expression in NK cells.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: October 18, 2016
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventor: Rifaat Safadi
  • MODULATION OF NLGn4 EXPRESSION, NK CELL ACTIVITY IN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
    Publication number: 20160115485
    Abstract: The present invention provides a method of treating, attenuating or preventing a liver disorder by inhibiting NGn4 expression and thereby modulating the activity of NK cells. The present invention further relates to diagnosing a liver disorder by evaluating NLGn4 expression in NK cells.
    Type: Application
    Filed: December 9, 2015
    Publication date: April 28, 2016
    Inventor: Rifaat SAFADI
  • Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD)
    Patent number: 9243294
    Abstract: The present invention provides a method of treating, attenuating or preventing a liver disorder by inhibiting NLGn4 expression and thereby modulating the activity of NK cells. The present invention further relates to diagnosing a liver disorder by evaluating NLGn4 expression in NK cells.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: January 26, 2016
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventor: Rifaat Safadi
  • MODULATION OF NLGn4 EXPRESSION, NK CELL ACTIVITY IN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
    Publication number: 20150094355
    Abstract: The present invention provides a method of treating, attenuating or preventing a liver disorder by inhibiting NLGn4 expression and thereby modulating the activity of NK cells. The present invention further relates to diagnosing a liver disorder by evaluating NLGn4 expression in NK cells.
    Type: Application
    Filed: September 30, 2014
    Publication date: April 2, 2015
    Inventor: Rifaat SAFADI
  • Glatiramer acetate for use as an immuno-modulatory agent
    Publication number: 20070197424
    Abstract: A method for the treatment of hepatic fibrotic injuries caused by various diseases, viral infections or toxic agents which involves the use of glatiramer acetate as an immuno-modulatory agent. The diseases to be treated are hepatic fibrosis and hepatic cellular carcinomas. Also disclose is the use of glatiramer acetate in the treatment of inflammatory bowel diseases. Additionally, disclosed are methods for screening for immuno-modulatory agents which are useful in the treatment of hepatic fibrosis, hepatic cellular carcinomas and inflammatory bowel diseases.
    Type: Application
    Filed: September 14, 2004
    Publication date: August 23, 2007
    Inventors: Scott Friedman, Rifaat Safadi